Explore more publications!

Asia Pacific Finance Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Pacific Finance Daily.

Press releases published on April 22, 2026

BrainChip to Unveil 2026 Future Technology Roadmap in Keynote Presentation
Financial Advisory Market Competitive Landscape Across Leading and Emerging Players
aiComply Launches NavigateCyber Financial Services to Support Banks Transitioning from FFIEC CAT to NIST CSF 2.0
From Quantum Cryptography to AI Data Centers: Public Companies Present at April 23 Virtual Investor Conference
Forward Edge-AI Appoints Brad Vier as Chief Technology Officer to Lead Next Generation Solutions
How Turkey’s CBI Program Serves as a Fast-Track U.S. E-2 Visa Pathway in 2026
Kneron Appoints Gene Lay, Founder of BioLegend, to Board of Directors
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Elevra Lithium Quarterly Activities Report
Rogers Communications Announces Voting Results from Annual General Meeting of Shareholders
Mirastar Federal Credit Union Launches Community Needs Assessment Survey to Deepen Community Listening and Advance Inclusive Financial Solutions
The Elmet Group Co. Announces Pricing of Upsized Initial Public Offering
Univest Securities, LLC Ranked 5th in the Q1 2026 U.S. PIPE and Private Placement Markets Investment Banking League Table by Number of Transactions
Century Next Financial Corporation Reports 1st Quarter 2026 Results
The 2026 NAB Show Wraps with Proof the Future of Media and Entertainment is Expanding Beyond Broadcasting
Racent Showcases sslTrus CLM at GOPS 2026, Highlighting Automated Certificate Management
SOUTHERN MISSOURI BANCORP REPORTS PRELIMINARY RESULTS FOR THIRD QUARTER OF FISCAL 2026; DECLARES QUARTERLY DIVIDEND OF $0.25 PER COMMON SHARE; CONFERENCE CALL SCHEDULED FOR THURSDAY, APRIL 23, AT 9:30 AM CENTRAL TIME
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Communiqué de presse :  Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions